Commentary|Podcasts|December 22, 2023

Treating Psoriasis While Providing Patient Support

Camille Lee discusses the impact of commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults, along with the value of patient assistance/affordability programs.

In this PC Podcast interview that originally aired for Pharmaceutical Executive, Camille Lee, UCB’s SVP and US head of immunology, dives into:

  • The history behind UCB's work in psoriasis
  • The significance behind UCB announcing the commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
  • How Bimzelx Navigate can be utilized as a resource for patients on this drug
  • What listeners should keep an eye out for in terms of UCB's rheumatology pipeline

The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud. The original video footage by Associate Editor Don Tracy can be viewed here.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Subscribe Now!

Related Content